NCT01277757 2018-12-19
Akt Inhibitor MK2206 in Treating Patients With Advanced Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
Clinical Trials
5 trialsNCT01344031 2018-07-23
MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT01263145 2017-08-25
MK2206 and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT01295632 2015-08-27
Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT01245205 2014-10-23
Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer
National Cancer Institute (NCI)
Phase 1 Completed